[Form 4/A] ProMIS Neurosciences Inc. Amended Insider Trading Activity
Title 19 Promis exercised purchase warrants to acquire common shares of ProMIS Neurosciences (PMN). On 07/25/2025 the reporting person exercised 119,800 Tranche A warrants, 119,800 Tranche B warrants and 119,800 Tranche C warrants, each exercised for one common share at an adjusted exercise price of $0.83518 per share (original tranche exercise prices were $2.02 for A and B, $2.50 for C). Each exercise resulted in issuance of 119,800 common shares per tranche, zero cash price reported for derivative value, and 345,316 common shares reported as beneficially owned following the transactions. The Form 4/A corrects an inadvertent prior disclosure of the exercise price. The remarks state that, based on the issuer's reported outstanding shares of 51,806,497, the reporting person鈥檚 ownership dropped below 10%.
Title 19 Promis ha esercitato warrant di acquisto per ottenere azioni ordinarie di ProMIS Neurosciences (PMN). In data 25/07/2025 il dichiarante ha esercitato 119.800 warrant Tranche A, 119.800 warrant Tranche B e 119.800 warrant Tranche C, ciascuno convertito in un鈥檃zione ordinaria al prezzo di esercizio rettificato di $0.83518 per azione (i prezzi di esercizio originali erano $2,02 per A e B e $2,50 per C). Ogni esercizio ha comportato l鈥檈missione di 119.800 azioni ordinarie per tranche, non 猫 stato riportato alcun corrispettivo in contanti per il valore del derivato, e dopo le operazioni risultano possedute beneficiariamente 345.316 azioni ordinarie. Il Form 4/A corregge una precedente comunicazione involontaria del prezzo di esercizio. Nelle note si precisa che, in base alle azioni in circolazione dichiarate dall鈥檈mittente pari a 51.806.497, la partecipazione del dichiarante 猫 scesa al di sotto del 10%.
Title 19 Promis ejerci贸 warrants de compra para adquirir acciones ordinarias de ProMIS Neurosciences (PMN). El 25/07/2025 la persona informante ejerci贸 119.800 warrants Tranche A, 119.800 Tranche B y 119.800 Tranche C, cada uno convertido en una acci贸n ordinaria a un precio de ejercicio ajustado de $0.83518 por acci贸n (los precios de ejercicio originales eran $2.02 para A y B y $2.50 para C). Cada ejercicio result贸 en la emisi贸n de 119.800 acciones ordinarias por tranche, no se report贸 precio en efectivo por el valor del derivado, y tras las transacciones se informaron 345.316 acciones ordinarias en propiedad beneficiaria. El Form 4/A corrige una divulgaci贸n inadvertida previa del precio de ejercicio. En las observaciones se indica que, seg煤n las acciones en circulaci贸n reportadas por el emisor de 51.806.497, la participaci贸n del informante cay贸 por debajo del 10%.
Title 19 Promis電� ProMIS Neurosciences(PMN)鞚� 氤错喌欤茧ゼ 旆摑頃橁赴 鞙勴暣 毵れ垬鞗岆煱韸鸽ゼ 頄夓偓頄堨姷雼堧嫟. 2025-07-25鞐� 氤搓碃鞚胳潃 119,800臧滌潣 Tranche A 鞗岆煱韸�, 119,800臧滌潣 Tranche B 鞗岆煱韸� 氚� 119,800臧滌潣 Tranche C 鞗岆煱韸鸽ゼ 臧侁皝 頄夓偓頃橃棳 臁办爼霅� 頄夓偓臧�瓴╈澑 $0.83518 per share鞐� 氤错喌欤� 頃� 欤茧 鞝勴櫂頄堨姷雼堧嫟(鞗愲灅 韸鸽灉旃� 頄夓偓臧�瓴╈潃 A路B $2.02, C $2.50). 臧� 頄夓偓搿� 韸鸽灉旃橂嫻 119,800欤� 氤错喌欤缄皜 氚滍枆霅橃棃瓿�, 韺岇儩靸來拡 臧�旃橃棎 雽�頃� 順勱笀 臧�瓴╈潃 氤搓碃霅橃 鞎婌晿鞙茧┌, 瓯半灅 頉� 齑� 345,316欤� 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 氤搓碃霅橃棃鞀惦媹雼�. Form 4/A電� 鞚挫爠鞐� 鞁れ垬搿� 瓿奠嫓霅� 頄夓偓臧�瓴╈潉 鞝曥爼頃� 瓴冹瀰雼堧嫟. 牍勱碃鞐愲姅 氚滍枆靷皜 氤搓碃頃� 51,806,497欤茧ゼ 旮办鞙茧 氤搓碃鞚胳潣 歆�攵勳澊 10% 氙鸽鞙茧 頃橂澖頄堧嫟瓿� 鞝來榾 鞛堨姷雼堧嫟.
Title 19 Promis a exerc茅 des warrants d鈥檃chat pour acqu茅rir des actions ordinaires de ProMIS Neurosciences (PMN). Le 25/07/2025, la personne d茅clarante a exerc茅 119 800 warrants de la Tranche A, 119 800 de la Tranche B et 119 800 de la Tranche C, chacun converti en une action ordinaire au prix d鈥檈xercice ajust茅 de $0.83518 par action (les prix d鈥檈xercice initiaux 茅taient de $2,02 pour A et B et $2,50 pour C). Chaque exercice a entra卯n茅 l鈥櫭﹎ission de 119 800 actions ordinaires par tranche, aucun prix en esp猫ces n鈥檃 茅t茅 d茅clar茅 pour la valeur du produit d茅riv茅, et 345 316 actions ordinaires ont 茅t茅 d茅clar茅es comme d茅tenues effectivement apr猫s les op茅rations. Le formulaire 4/A corrige une divulgation ant茅rieure involontaire du prix d鈥檈xercice. Les remarques indiquent que, sur la base des actions en circulation d茅clar茅es par l鈥櫭﹎etteur de 51 806 497, la participation du d茅clarant est pass茅e en dessous de 10%.
Title 19 Promis hat Kauf-Warrants ausge眉bt, um Stammaktien von ProMIS Neurosciences (PMN) zu erwerben. Am 25.07.2025 眉bte die meldende Person 119.800 Tranche-A-Warrants, 119.800 Tranche-B-Warrants und 119.800 Tranche-C-Warrants aus, jeweils zum Umtausch in eine Stammaktie zu einem bereinigten Aus眉bungspreis von $0.83518 pro Aktie (urspr眉ngliche Aus眉bungspreise: A und B $2,02, C $2,50). Jede Aus眉bung f眉hrte zur Ausgabe von 119.800 Stammaktien pro Tranche, es wurde kein Bargeldbetrag f眉r den Derivatewert gemeldet, und nach den Transaktionen wurden 345.316 Stammaktien als wirtschaftlich gehalten gemeldet. Das Formular 4/A korrigiert eine versehentliche fr眉here Angabe des Aus眉bungspreises. In den Bemerkungen hei脽t es, dass die Beteiligung der meldenden Person anhand der vom Emittenten berichteten ausstehenden Aktien von 51.806.497 unter 10% gefallen ist.
- Corrected disclosure of the exercise price from $0.83158 to $0.83518, improving filing accuracy
- Issuer-accepted exercise achieved, converting warrants into common shares and clarifying beneficial ownership
- Reporting person鈥檚 ownership dropped below 10% based on issuer's reported 51,806,497 outstanding shares
- Initial filing contained an incorrect exercise price, requiring an amendment to correct material transaction detail
Insights
TL;DR Insider exercised warrants materially below original strike prices, increasing common shares outstanding and correcting a prior pricing error.
The exercise of 359,400 warrants (119,800 per tranche) at an accepted price of $0.83518 materially changes the reporting person鈥檚 immediate share count while reflecting amendment-level housekeeping to correct the disclosed exercise price. This is an issuer-accepted private exercise arrangement reducing the effective price paid versus original tranche strikes; the filing notes resulting beneficial ownership of 345,316 shares and that ownership fell below 10% using the issuer's stated outstanding share count of 51,806,497. For investors, the transaction is primarily a change in ownership composition and disclosure accuracy rather than a direct statement about operational performance.
TL;DR Amendment clarifies exercise price and reports changes to insider ownership percentage; governance disclosure corrected.
The Form 4/A aligns insider reporting with the issuer-approved exercise terms and corrects a numeric error in the initial filing. Accurate disclosure of exercise prices and resultant ownership percentages is important for compliance and market transparency. The remark that ownership fell below 10%鈥攂ased on the issuer's reported outstanding shares鈥攈ighlights the importance of timely issuer share counts in Section 16 calculations. This amendment addresses disclosure integrity rather than alleging misconduct.
Title 19 Promis ha esercitato warrant di acquisto per ottenere azioni ordinarie di ProMIS Neurosciences (PMN). In data 25/07/2025 il dichiarante ha esercitato 119.800 warrant Tranche A, 119.800 warrant Tranche B e 119.800 warrant Tranche C, ciascuno convertito in un鈥檃zione ordinaria al prezzo di esercizio rettificato di $0.83518 per azione (i prezzi di esercizio originali erano $2,02 per A e B e $2,50 per C). Ogni esercizio ha comportato l鈥檈missione di 119.800 azioni ordinarie per tranche, non 猫 stato riportato alcun corrispettivo in contanti per il valore del derivato, e dopo le operazioni risultano possedute beneficiariamente 345.316 azioni ordinarie. Il Form 4/A corregge una precedente comunicazione involontaria del prezzo di esercizio. Nelle note si precisa che, in base alle azioni in circolazione dichiarate dall鈥檈mittente pari a 51.806.497, la partecipazione del dichiarante 猫 scesa al di sotto del 10%.
Title 19 Promis ejerci贸 warrants de compra para adquirir acciones ordinarias de ProMIS Neurosciences (PMN). El 25/07/2025 la persona informante ejerci贸 119.800 warrants Tranche A, 119.800 Tranche B y 119.800 Tranche C, cada uno convertido en una acci贸n ordinaria a un precio de ejercicio ajustado de $0.83518 por acci贸n (los precios de ejercicio originales eran $2.02 para A y B y $2.50 para C). Cada ejercicio result贸 en la emisi贸n de 119.800 acciones ordinarias por tranche, no se report贸 precio en efectivo por el valor del derivado, y tras las transacciones se informaron 345.316 acciones ordinarias en propiedad beneficiaria. El Form 4/A corrige una divulgaci贸n inadvertida previa del precio de ejercicio. En las observaciones se indica que, seg煤n las acciones en circulaci贸n reportadas por el emisor de 51.806.497, la participaci贸n del informante cay贸 por debajo del 10%.
Title 19 Promis電� ProMIS Neurosciences(PMN)鞚� 氤错喌欤茧ゼ 旆摑頃橁赴 鞙勴暣 毵れ垬鞗岆煱韸鸽ゼ 頄夓偓頄堨姷雼堧嫟. 2025-07-25鞐� 氤搓碃鞚胳潃 119,800臧滌潣 Tranche A 鞗岆煱韸�, 119,800臧滌潣 Tranche B 鞗岆煱韸� 氚� 119,800臧滌潣 Tranche C 鞗岆煱韸鸽ゼ 臧侁皝 頄夓偓頃橃棳 臁办爼霅� 頄夓偓臧�瓴╈澑 $0.83518 per share鞐� 氤错喌欤� 頃� 欤茧 鞝勴櫂頄堨姷雼堧嫟(鞗愲灅 韸鸽灉旃� 頄夓偓臧�瓴╈潃 A路B $2.02, C $2.50). 臧� 頄夓偓搿� 韸鸽灉旃橂嫻 119,800欤� 氤错喌欤缄皜 氚滍枆霅橃棃瓿�, 韺岇儩靸來拡 臧�旃橃棎 雽�頃� 順勱笀 臧�瓴╈潃 氤搓碃霅橃 鞎婌晿鞙茧┌, 瓯半灅 頉� 齑� 345,316欤� 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 氤搓碃霅橃棃鞀惦媹雼�. Form 4/A電� 鞚挫爠鞐� 鞁れ垬搿� 瓿奠嫓霅� 頄夓偓臧�瓴╈潉 鞝曥爼頃� 瓴冹瀰雼堧嫟. 牍勱碃鞐愲姅 氚滍枆靷皜 氤搓碃頃� 51,806,497欤茧ゼ 旮办鞙茧 氤搓碃鞚胳潣 歆�攵勳澊 10% 氙鸽鞙茧 頃橂澖頄堧嫟瓿� 鞝來榾 鞛堨姷雼堧嫟.
Title 19 Promis a exerc茅 des warrants d鈥檃chat pour acqu茅rir des actions ordinaires de ProMIS Neurosciences (PMN). Le 25/07/2025, la personne d茅clarante a exerc茅 119 800 warrants de la Tranche A, 119 800 de la Tranche B et 119 800 de la Tranche C, chacun converti en une action ordinaire au prix d鈥檈xercice ajust茅 de $0.83518 par action (les prix d鈥檈xercice initiaux 茅taient de $2,02 pour A et B et $2,50 pour C). Chaque exercice a entra卯n茅 l鈥櫭﹎ission de 119 800 actions ordinaires par tranche, aucun prix en esp猫ces n鈥檃 茅t茅 d茅clar茅 pour la valeur du produit d茅riv茅, et 345 316 actions ordinaires ont 茅t茅 d茅clar茅es comme d茅tenues effectivement apr猫s les op茅rations. Le formulaire 4/A corrige une divulgation ant茅rieure involontaire du prix d鈥檈xercice. Les remarques indiquent que, sur la base des actions en circulation d茅clar茅es par l鈥櫭﹎etteur de 51 806 497, la participation du d茅clarant est pass茅e en dessous de 10%.
Title 19 Promis hat Kauf-Warrants ausge眉bt, um Stammaktien von ProMIS Neurosciences (PMN) zu erwerben. Am 25.07.2025 眉bte die meldende Person 119.800 Tranche-A-Warrants, 119.800 Tranche-B-Warrants und 119.800 Tranche-C-Warrants aus, jeweils zum Umtausch in eine Stammaktie zu einem bereinigten Aus眉bungspreis von $0.83518 pro Aktie (urspr眉ngliche Aus眉bungspreise: A und B $2,02, C $2,50). Jede Aus眉bung f眉hrte zur Ausgabe von 119.800 Stammaktien pro Tranche, es wurde kein Bargeldbetrag f眉r den Derivatewert gemeldet, und nach den Transaktionen wurden 345.316 Stammaktien als wirtschaftlich gehalten gemeldet. Das Formular 4/A korrigiert eine versehentliche fr眉here Angabe des Aus眉bungspreises. In den Bemerkungen hei脽t es, dass die Beteiligung der meldenden Person anhand der vom Emittenten berichteten ausstehenden Aktien von 51.806.497 unter 10% gefallen ist.
FAQ
What warrants did Title 19 Promis exercise in the Form 4/A for PMN?
At what price were the PMN warrants exercised?
How many common shares did the reporting person beneficially own after these transactions?
Did the filing amend any previously reported information?
Did the reporting person remain a 10% owner after the amendment?
